logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type [see all tables in this series...]

Part (ii) All clients with opioids as primary drug type: number of episodes reporting the stated drug as secondary

CountryOpioidsCocaineOther stimulantsHypnotics/sedativesHallucinogensVolatile substancesCannabisAlcoholOthers
Bulgaria2425321002855183
Czech Republic14883212733227141259
Denmark37617213526831134382462768
Germany2724255363145307612309369984621236
Ireland410782110862939263474
Greece4759624287413231186855091
Spain330168812046526213329087539
France112720152024301049216173410691
Italy92989151631742665976530227434810
Cyprus105627280567266
Latvia9332700124118
Luxembourg271032546518225314
Malta031223295472407101107
Netherlands2927572043101102131478
Austria622596488567113126723715182
Slovakia6141461011468140
Finland7811332481010027588
Sweden811458120307843400
United Kingdom8136217472096755860269396474093278
Total398944334091951545024492703086414688165312

Notes:

 Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients. 

 ‘Opioids’ include: heroin, methadone, other opioids; ‘Cocaine’ includes: cocaine HCl, crack cocaine; ‘Stimulants’ include: amphetamines, MDMA and derivates, other stimulants: ‘Cannabis’ can include herb or resin. For each client up to four secondary drugs can be reported. 

 A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. 

 See also 'General notes for interpreting data’ on the Explanatory notes and help page

Sources:

 Reitox national reports 2007.  

(see the help page for information about formats etc.)

Page last updated: Monday, 14 July 2008